The evidence that drugs like SGL2s and GLP-1 receptor agonists will prolong life expectancy of patients who suffer from heart failure is strong and many patients in the US were started on these drugs before 2026.  Someone needs to study how removing these drugs from heart patients therapy regimen affects their quality of life or are CVD patients rapidly declining after sudden withdrawal of a group of drugs that we knew were decreasing deaths from heart failure but not precisely how. It’s critical to determine what is happening to patients who suddenly stop taking medication regimens that could cost over $20,000 annually for some patients who were on expensive blood thinners in addition to the other drugs that are also still covered by patents. In January of 2026,  Seniors on the Medicare Part D “Extra Help” program or state prescription drug plans that helped people who had expensive drug regimens were thrown under the bus so tax cuts could Make America Great although we don’t know for whom. Heart failure patients are not faring well during the early stages of withdrawal of the SGL-2 drugs and some are suffering from sudden edema, severe hypertension and cardiac arrhythmias. Since they have gone off of the expensive blood thinners, they are taking the cheap blood thinner that has Trump’s guarantee that it will keep your blood from getting “thick”.  America is suffering from heart failure all over the world.